Greater Paris University Hospitals, AP-HP and IntegraGen Agree to a Research Partnership to Develop a Common Platform for High-Throughput Sequencing

Regulatory News:

The Greater Paris University Hospitals, AP-HP and the molecular genomics company INTEGRAGEN (Paris:ALINT) announced today the signature of an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives.

This three-year research partnership aligns with a major objective of the AP-HP’s 2015-2019 Strategic Plan related to providing clinicians and patients access to newer health innovations and technological advancements.

Through the framework of this agreement, researchers, clinicians, and biologists of the AP-HP, one of the largest patient referral center in Europe, will benefit from IntegraGen’s experience and expertise in large scale, industrial high throughput sequencing projects and its ability to deliver high quality data. This represents a major breakthrough for researchers at AP-HP since some were obliged to send DNA abroad to be sequenced prior to this agreement. This agreement represents an essential first step in the development of a formalized national personalized medicine initiative as a part of the French Plan for Genomic Medicine 2025.

The current initiative will enable sequencing data collected from biological samples to be transformed into genomic information and molecular diagnostic tools. The common high-throughput sequencing platform developed as a result of this agreement will be utilized for research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry. Researchers utilizing this platform will have access to an integrated solution ecompassing all stages of genomic analysis, from the collection of the biological sample to the delivery of sequencing results.

"Sequencing is a complex process requiring perfect control of all stages of the analysis of biological samples. The bio-informatic analysis of the large amounts of sequencing data is also a major challenge,” stated Bertrand Fontaine, Vice President Research of the Executive Board of the AP-HP. "We are counting on our partnership with IntegraGen and the establishment of a pooled AP-HP bio-informatics platform to strengthen our expertise in this area. This partnership will also assist our biologists to better analyze raw sequencing data, ultimately enabling them to better study the correlation between phenotype and genetic variants."

The framework of the current agreement will also allow for the development of additional ambitious research projects and cooperative initiatives with outside research partners such as academic universities and INSERM.

"IntegraGen is extremely proud to develop a sequencing partnership for research projects and clinical research initiatives which will be dedicated to all AP-HP,” said Bernard Courtieu, IntegraGen’s CEO. "This is a major step in the growth of IntegraGen and again demonstrates our ability to provide expert solutions which meet the need of researchers and leads the way for the clinical adoption of molecular and personalized medicine advances. This strategic partnership demonstrates the recognition of the quality results IntegraGen’s provides and the expertise we have with sequencing platforms and advanced technologies, confirming our leadership among global companies operating in this field."

ABOUT THE AP-HP

The Greater Paris University Hospitals, AP-HP is the Paris area’s University Medical Center (UMC) and the leading UMC in Europe. Its 39 hospitals treat over 8 million patients each year either in consultation, for emergency care, for scheduled hospitalizations, or for home hospitalization. The AP-HP provides a public health service for all, 24h a day as a necessity for patients and with pride. The AP-HP is the largest employer in the Paris region with 95,000 people including doctors, researchers, paramedicals, administrative staff and workers. For more information about the AP-HP visit www.aphp.fr.

ABOUT INTEGRAGEN

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2015, IntegraGen had 37 employees and had generated revenue of €5.6 million in 2015. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006254/en/